SaNOtize develops nitric oxide-based therapeutics using its proprietary Nitric Oxide Releasing Solution (NORS) platform, with a lead product of a nitric oxide nasal spray (NONS) for treatment and prevention of COVID-19. NONS has shown rapid reductions in SARS-CoV-2 viral burden in clinical trials (Phase 2 and a Phase 3 study) and decreased infection risk in an observational prevention study. The company reports Phase 3 results showing 94% and 99% reductions in viral burden within 24 and 48 hours, respectively, and prior Phase 2 results with similar rapid viral RNA reductions. SaNOtize plans to expand its global Phase 3 NONS prevention trial, aiming to recruit up to 3,000 participants in Canada and Sri Lanka, and to pursue regulatory approval in the United States and Canada. NONS is already marketed as a medical device under brand names VirX and enovid in several countries, has emergency use approval in India for certain adult patients, and holds a CE mark in the EU. The company emphasizes a strong safety profile for its technology and seeks to broaden research across multiple therapeutic applications and delivery formats.

Total raised

$24M

Funding rounds

1

Latest round

Series B

Latest activity

Aug 2022